The global dermatology market is performing weakly, not only due to a limited number of new innovative product development and launches, but also to increasing generic competition. Anti-infective treatments continue to represent the most important component of the dermatology market, accounting for 31% of the entire market. Anti-infective products are most likely to succeed in clinical trial, have an 80% success rate compared to the next highest drug class at 40%, and are also the quickest to market.
There is an unmet medical need for new anti-infective products considering the dramatic increase in resistance towards classical antibiotics by certain microorganisms. This enables us to create new topical products and/or prolong patent life of current products.
The primary target for DermaGen’s products is the large and fast growing market need for new innovative local anti-infective products.
The global anti-infective market by drug category.
Market for anti-infective products
Broad-spectrum, multi-indication new anti-infective drugs generally have huge potential shortly after market introduction. This makes them ideal candidates for drug development from the perspective of pharmaceutical companies.
The antibacterial market in the near future is set for a period of significant change with key products facing patent expiry, resistant pathogens posing increasingly difficult problems and the continuing rise of infections in the hospital population that pose a significant challenge due to the emergence of antimicrobial resistance. The majority of the growth of the antibacterial market will be driven by uptake of novel or generic products, while current leaders will face tough challenges to maintain sales.
These imminent changes offer a good opportunity for DermaGen to succeed and prosper in the anti-infective drug market for topical therapeutics involving AMPs. Moreover, our technology facilitates rapid product development with preclinical and clinical proof of concept within 3 years.